

References

Tweet Three

Vitaloni M, Botto-van Bemden A, Sciortino R, et al. A patients' view of OA: the Global Osteoarthritis Patient Perception Survey (GOAPPS), a pilot study. *BMC Musculoskelet Disord*. 2020;21(1). doi:10.1186/s12891-020-03741-0

Tweet Four

Jackson J, Iyer R, Mellor J, Wei W. The burden of pain associated with osteoarthritis in the hip or knee from the patient's perspective: a multinational cross-sectional study. *Adv Ther*. 2020;37(9):3985-3999. doi:10.1007/s12325-020-01445-4

Tweet Six

Bemden AB-van, Eakin G, Sciortino R, et al. The global osteoarthritis patient perception survey (GOAPPS): a pilot study. *Osteoarthr and Cartil*. 2019;27. doi:10.1016/j.joca.2019.02.356

Tweet Seven

Saeed M. National estimates of pain medication use in patients with osteoarthritis [abstract]. *Arthritis Rheumatol*. 2019;71(suppl 10). Accessed April 5, 2021. <https://acrabstracts.org/abstract/national-estimates-of-pain-medication-use-in-patients-with-osteoarthritis/>

Tweet Eight

Lane NE, Corr M. Anti-NGF treatments for pain—two steps forward, one step back? *Nat Rev Rheumatol*. 2017;13(2):76-78. doi:10.1038/nrrheum.2016.224

Tweet Nine

Berenbaum F, Blanco FJ, Guermazi A, et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. *Ann Rheum Dis*. 2020;79:800-810.

Tweet Eleven

Berenbaum F, Blanco FJ, Guermazi A, et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. *Ann Rheum Dis*. 2020;79:800-810.

Carrino J, et al. ACR Convergence 2020; November 5-9, 2020. Abstract 1644.

Dakin P, et al. *Arthritis Rheumatol*. 2019;71:1824-1834

Tweet Twelve

Hunter D, Neogi T, Churchill M, et al. Clinically important improvements in patients with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized nsaid-controlled study [abstract]. *Arthritis Rheumatol*. 2020;72(suppl 10). Accessed April 5, 2021. <https://acrabstracts.org/abstract/clinically-important-improvements-in-patients-with-osteoarthritis-treated-with-subcutaneous-tanezumab-results-from-a-56-week-randomized-nsaid-controlled-study/>

Tweet Thirteen

Dakin P, DiMartino SJ, Gao H, et al. The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: a phase iib/iii double-blind, placebo-controlled, randomized clinical trial. *Arthritis Rheumatol.* 2019;71(11):1824-1834. doi:10.1002/art.41012

Tweet Fourteen

Dakin P, DiMartino SJ, Gao H, et al. The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: a phase iib/iii double-blind, placebo-controlled, randomized clinical trial. *Arthritis Rheumatol.* 2019;71(11):1824-1834. doi:10.1002/art.41012

Tweet Sixteen

Latourte A, Kloppenburg M, Richette P. Emerging pharmaceutical therapies for osteoarthritis. *Nat Rev Rheumatol.* 2020;16(12):673-688. doi:10.1038/s41584-020-00518-6

Tweet Seventeen

Latourte A, Kloppenburg M, Richette P. Emerging pharmaceutical therapies for osteoarthritis. *Nat Rev Rheumatol.* 2020;16(12):673-688. doi:10.1038/s41584-020-00518-6

Glossary

CJSE, composite joint safety endpoint
DMOADs, disease-modifying osteoarthritis drugs
EQ-5D-5L VAS, EuroQol 5-dimension 5-level visual analogue scale
FM, family medicine
GABA, gamma-aminobutyric acid
GOAPPS, Global Osteoarthritis Patient Perception Survey
GP, general practitioner
IM, internal medicine
IL, interleukin
mg, milligram
mod, moderate
NGF, nerve growth factor
NGF-abs, nerve growth factor antibodies
NHANES, National Health and Nutrition Examination Survey
No., number
NP, nurse practitioner
NSAIDs, nonsteroidal anti-inflammatory drugs
OA, osteoarthritis
Ortho, orthopedist
PBO, placebo
PA, physician assistant
PCP, primary care provider
PGA, patient global assessment
Ph3, phase three
QOL, quality of life
RCT, randomized clinical trials
RN, registered nurse
RPOA, rapidly progressing osteoarthritis
sev, severe
SIF, subchondral insufficiency fracture
SOC, standard of care
TCZ, tocilizumab
TEAEs, treatment emergent adverse events
TJRs, total joint replacements
TrkA, tropomyosin receptor kinase A
vs, versus
w/, with
w/o, without
WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index
WPAI: SHP, Work Productivity and Impairment Questionnaire: Specific Health Problem